Queiroz Dayane Priscilla de Souza, Carollo Carlos Alexandre, Kadri Mônica Cristina Toffoli, Rizk Yasmin Silva, Araujo Vanessa Carneiro Pereira de, Monteiro Paulo Eduardo de Oliveira, Rodrigues Patrik Oening, Oshiro Elisa Teruya, Matos Maria de Fátima Cepa, Arruda Carla Cardozo Pinto de
Laboratório de Parasitologia Humana, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brasil.
Laboratório de Produtos Naturais e Espectrometria de Massas, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brasil.
Mem Inst Oswaldo Cruz. 2016 Mar;111(3):147-54. doi: 10.1590/0074-02760150307. Epub 2016 Feb 19.
The polar hydroethanolic extract from Selaginella sellowii(SSPHE) has been previously proven active on intracellular amastigotes (in vitro test) and now was tested on hamsters infected with Leishmania (Leishmania) amazonensis (in vivo test). SSPHE suppressed a 100% of the parasite load in the infection site and draining lymph nodes at an intralesional dose of 50 mg/kg/day × 5, which was similar to the results observed in hamsters treated with N-methylglucamine antimonate (Sb) (28 mg/Kg/day × 5). When orally administered, SSPHE (50 mg/kg/day × 20) suppressed 99.2% of the parasite load in infected footpads, while Sb suppressed 98.5%. SSPHE also enhanced the release of nitric oxide through the intralesional route in comparison to Sb. The chemical fingerprint of SSPHE by high-performance liquid chromatography with diode-array detection and tandem mass spectrometry showed the presence of biflavonoids and high molecular weight phenylpropanoid glycosides. These compounds may have a synergistic action in vivo. Histopathological study revealed that the intralesional treatment with SSPHE induced an intense inflammatory infiltrate, composed mainly of mononuclear cells. The present findings reinforce the potential of this natural product as a source of future drug candidates for American cutaneous leishmaniasis.
卷柏（Selaginella sellowii）的极性乙醇提取物（SSPHE）先前已被证明对细胞内无鞭毛体具有活性（体外试验），现在对感染亚马逊利什曼原虫（Leishmania）的仓鼠进行了测试（体内试验）。SSPHE以50 mg/kg/天×5的病灶内剂量抑制了感染部位和引流淋巴结中100%的寄生虫负荷，这与用葡甲胺锑酸盐（Sb）（28 mg/Kg/天×5）治疗的仓鼠中观察到的结果相似。口服时，SSPHE（50 mg/kg/天×20）抑制了感染足垫中99.2%的寄生虫负荷，而Sb抑制了98.%. 与Sb相比，SSPHE还通过病灶内途径增强了一氧化氮的释放。通过二极管阵列检测和串联质谱的高效液相色谱法对SSPHE进行的化学指纹图谱显示存在双黄酮和高分子量苯丙烷糖苷。这些化合物在体内可能具有协同作用。组织病理学研究表明，SSPHE的病灶内治疗诱导了强烈的炎症浸润，主要由单核细胞组成。目前的研究结果强化了这种天然产物作为美洲皮肤利什曼病未来候选药物来源的潜力
